This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	K-Ras (KRAS); NF-κB; TANK-binding kinase 1 (TBK1)	<p>A study in cell culture suggests that inhibiting TBK1 could help treat K-Ras-driven cancers.</p> <p>In human cancer cell lines with activating K-Ras mutations, small hairpin RNA-mediated knockdown of TBK1 increased cell death compared with that in cell lines expressing wild-type K-Ras. In cell lines expressing K-Ras mutations, TBK1 activated NF-κB antiapoptotic signals. Next steps include experiments to show that TBK1 is essential for tumor maintenance.</p> <p>SciBX 2(42); doi:10.1038/scibx.2009.1562 Published online Oct. 29, 2009</p>	Work unpatented; licensing status undisclosed	<p>Barbie, D.A. <i>et al. Nature</i>; published online Oct. 21, 2009; doi:10.1038/nature08460</p> <p>Contact: William Hahn, Dana-Farber Cancer Institute, Boston, Mass. e-mail: william_hahn@dfci.harvard.edu</p>